Hepatic Pathobiology of Iron Overload

Ruddell, Richard G.; Ramm, Grant A.

doi:10.1007/978-1-60327-485-2_18

Cited by 4 publications

(3 citation statements)

References 183 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall risk for hepatocellular carcinoma in patients suffering from hemochromatosis is 6-10%. It is preceded by the development of liver cirrhosis and is responsible for 25-45% of all premature deaths associated with hemochromatosis (417). There is some evidence to suggest that iron status may be related to other cancers, but more research is needed to establish a causal role (418).…”

Section: Current Controversy Related To the Possible Role Of Iron In mentioning

confidence: 99%

Biomarkers of Nutrition for Development (BOND)—Iron Review

Lynch¹,

Pfeiffer

Georgieff

et al. 2018

The Journal of Nutrition

250

193

View full text Add to dashboard Cite

This is the fifth in the series of reviews developed as part of the Biomarkers of Nutrition for Development (BOND) program. The BOND Iron Expert Panel (I-EP) reviewed the extant knowledge regarding iron biology, public health implications, and the relative usefulness of currently available biomarkers of iron status from deficiency to overload. Approaches to assessing intake, including bioavailability, are also covered. The report also covers technical and laboratory considerations for the use of available biomarkers of iron status, and concludes with a description of research priorities along with a brief discussion of new biomarkers with potential for use across the spectrum of activities related to the study of iron in human health.The I-EP concluded that current iron biomarkers are reliable for accurately assessing many aspects of iron nutrition. However, a clear distinction is made between the relative strengths of biomarkers to assess hematological consequences of iron deficiency versus other putative functional outcomes, particularly the relationship between maternal and fetal iron status during pregnancy, birth outcomes, and infant cognitive, motor and emotional development. The I-EP also highlighted the importance of considering the confounding effects of inflammation and infection on the interpretation of iron biomarker results, as well as the impact of life stage. Finally, alternative approaches to the evaluation of the risk for nutritional iron overload at the population level are presented, because the currently designated upper limits for the biomarker generally employed (serum ferritin) may not differentiate between true iron overload and the effects of subclinical inflammation.

show abstract

Section: Current Controversy Related To the Possible Role Of Iron In mentioning

confidence: 99%

Biomarkers of Nutrition for Development (BOND)—Iron Review

Lynch¹,

Pfeiffer

Georgieff

et al. 2018

The Journal of Nutrition

250

193

View full text Add to dashboard Cite

show abstract

“…This reaction rapidly changes free Fe in the form of Fe 3+ to Fe 2+ by a reduction reaction with hydrogen peroxide. In addition, this reaction leads to the production of hydroxyl radicals that can cause biological damage [5,6]. Iron is an essential trace element that can be toxic for cells and organisms; consequently, several mechanisms are implemented to regulate precisely Fe absorption, transport, and storage.…”

Section: Iron Normal Metabolismmentioning

confidence: 99%

Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy

Lelièvre

Sancey

Coll

et al. 2020

Cancers

View full text Add to dashboard Cite

Iron (Fe) is a trace element that plays essential roles in various biological processes such as DNA synthesis and repair, as well as cellular energy production and oxygen transport, and it is currently widely recognized that iron homeostasis is dysregulated in many cancers. Indeed, several iron homeostasis proteins may be responsible for malignant tumor initiation, proliferation, and for the metastatic spread of tumors. A large number of studies demonstrated the potential clinical value of utilizing these deregulated proteins as prognostic and/or predictive biomarkers of malignancy and/or response to anticancer treatments. Additionally, the iron present in cancer cells and the importance of iron in ferroptosis cell death signaling pathways prompted the development of therapeutic strategies against advanced stage or resistant cancers. In this review, we select relevant and promising studies in the field of iron metabolism in cancer research and clinical oncology. Besides this, we discuss some co-existing discrepant findings. We also present and discuss the latest lines of research related to targeting iron, or its regulatory pathways, as potential promising anticancer strategies for human therapy. Iron chelators, such as deferoxamine or iron-oxide-based nanoparticles, which are already tested in clinical trials, alone or in combination with chemotherapy, are also reported.

show abstract

“…to Fe 2+ by a reduction reaction with hydrogen peroxide. In addition, this reaction leads to the production of hydroxyl radicals that can cause biological damage [5,6]. Iron is an essential trace element that can be toxic for cells and organisms, consequently, several mechanisms are implemented to regulate precisely Fe absorption, transport, and storage.…”

Section: Iron (Fe) Normal Metabolismmentioning

confidence: 99%

Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy

Lelièvre

Sancey

Coll

et al. 2020

Preprint

View full text Add to dashboard Cite

Iron (Fe) is a trace element that plays essential roles in various biological processes such as DNA synthesis and repair, as well as cellular energy production, or oxygen transport, and it is currently widely recognized that iron homeostasis is dysregulated in many cancers. Indeed, several iron homeostasis proteins may be responsible for malignant tumor initiation, proliferation, and for metastatic spread of tumors. A large number of studies demonstrated the potential clinical value of turning these deregulated proteins as prognostic and/or predictive biomarkers of malignancy and /or response to anticancer treatments. Additionally, the iron addiction of cancer cells and the importance of iron in ferroptosis cell death signaling pathways prompted the development of therapeutic strategies against advanced stage or resistant cancers. In this review, we selected relevant and promising studies in the field of iron metabolism in cancer research and clinical oncology. Besides, we discuss some co-existing discrepant findings. We will also present and discuss the latest lines of research related to targeting iron, or its regulatory pathways, as potential promising anti-cancer strategies for human therapy. Iron chelators, such as deferoxamine or iron-oxide based nanoparticles, which are already tested in clinical trials, alone or in combination with chemotherapy will also be reported.

show abstract

Hepatic Pathobiology of Iron Overload

Cited by 4 publications

References 183 publications

Biomarkers of Nutrition for Development (BOND)—Iron Review

Biomarkers of Nutrition for Development (BOND)—Iron Review

Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy

Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy

Contact Info

Product

Resources

About